Hormone Therapy in 65-Year-Old Women: Not Recommended for New Initiation
Hormone therapy should NOT be initiated in a 65-year-old woman for the first time, but may be continued if already established before age 60 with careful risk-benefit reassessment.
Key Decision Framework
The critical distinction is whether this woman is:
- Starting hormone therapy for the first time at age 65 → Do NOT initiate
- Already on hormone therapy started before age 60 → May continue with annual reassessment
For Women Initiating Hormone Therapy After Age 65
Do not start hormone therapy. The Endocrine Society explicitly recommends against initiating MHT in women ≥60 years or >10 years past menopause unless they have bothersome vasomotor symptoms, no contraindications, and acceptable cardiovascular/breast cancer risk 1. The USPSTF recommends against using hormone therapy for chronic disease prevention in postmenopausal women of any age 2.
The most recent high-quality evidence (2026) demonstrates that initiating hormone therapy at age 65 or older is associated with dramatically increased risks:
- Cancer: 2.2-fold increased hazard (HR: 2.216,95% CI: 1.833-2.677)
- Stroke: 2.7-fold increased hazard (HR: 2.695,95% CI: 2.358-3.079) 3
For Women Already on Hormone Therapy Started Before Age 60
Continuation may be appropriate if:
- She has persistent bothersome vasomotor symptoms
- Cardiovascular risk remains low-to-moderate
- No new contraindications have developed
- Annual risk-benefit reassessment supports continuation 1
Recent Medicare data (2024) shows that continuing estrogen monotherapy beyond age 65 was associated with significant risk reductions in mortality (19%), breast cancer (16%), cardiovascular events (5-11%), and dementia (2%) 4. However, this contradicts the 2026 Israeli cohort study showing increased risks 3.
Specific Risk Assessment Required
Cardiovascular Risk Stratification
- High CVD risk: Use non-hormonal therapies instead 1
- Moderate CVD risk: If continuing therapy, use transdermal estradiol with micronized progesterone (if uterus present) 1
- Low CVD risk: Standard formulations acceptable if already established
Breast Cancer Risk
- Inform about increased breast cancer risk with estrogen-progestogen therapy (10-19% increase) 4
- Estrogen monotherapy shows reduced breast cancer risk in some studies 4
- Ensure age-appropriate screening adherence 1
Optimal Formulations if Continuing Beyond Age 65
Transdermal estradiol is strongly preferred over oral formulations because:
- Lower venous thromboembolism risk 5, 4
- Better cardiovascular safety profile 1, 6
- Reduced stroke risk compared to oral preparations
If uterus present: Combine with micronized progesterone or low-dose progestin (transdermal/vaginal routes preferred) 4
Dose: Use lowest effective dose - low-dose preparations show greater risk reductions than medium/high doses 4
Critical Pitfalls to Avoid
Do not initiate hormone therapy for chronic disease prevention (osteoporosis, cardiovascular disease, dementia) at age 65 - this is explicitly contraindicated 2
Do not use compounded bioidentical hormones - FDA has not approved these for any indication and safety is unestablished 2
Do not continue therapy indefinitely without reassessment - annual reevaluation is mandatory 1
Do not ignore the "timing hypothesis" - benefits are time-dependent, with favorable effects only when initiated within 10 years of menopause 5, 7
Annual Reassessment Checklist
For women continuing therapy beyond age 65:
- Persistent vasomotor symptoms requiring treatment?
- New cardiovascular risk factors developed?
- Breast cancer screening up-to-date?
- Any unscheduled bleeding (requires endometrial evaluation) 1
- Patient still willing to accept risks for symptom relief?
- Treatment goals still being met?
Alternative Approaches
For symptomatic women age 65+ where systemic hormone therapy is inappropriate:
- Genitourinary symptoms only: Low-dose vaginal estrogen (not systemic absorption) 7
- Vasomotor symptoms: Non-hormonal therapies (SSRIs, SNRIs, gabapentin, fezolinetant) 1
Evidence Conflicts
The 2026 Israeli study 3 showing dramatically increased risks contradicts the 2024 Medicare study 4 showing protective effects. The Medicare study's findings of reduced mortality and cancer with continuation may reflect healthy-user bias. Given this contradiction, err on the side of caution: prioritize the most recent evidence showing harm with late initiation 3, while acknowledging that carefully selected women already on therapy may continue with intensive monitoring.